BioRestorative Therapies BRTX
NASDAQ BRTX
$1.53 -0.01 (-0.65%)
As of: Oct 21, 2026 · 3:25 PM EDT

BioRestorative Therapies (BRTX) Current Deferred Revenue (2014 - 2025)

Updated

BioRestorative Therapies (BRTX) posted Current Deferred Revenue of $150,000 for Q1 2025.

Analysis

BioRestorative Therapies (BRTX) Current Deferred Revenue (2014 - 2025) Analysis & Trends

At the end of FY2014, BioRestorative Therapies' Current Deferred Revenue came in at $164,349.

  • The Q1 2025 figure stands as the highest quarterly Current Deferred Revenue since Q1 2015.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn
10 BioRestorative Therapies 687,973.67 -23.25 Mn 17,964.00
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2025 150,000.00
Sep 30, 2015 101,527.00
Jun 30, 2015 114,118.00
Mar 31, 2015 210,882.00
Dec 31, 2014 164,349.00
Sep 30, 2014 154,662.00
Jun 30, 2014 224,975.00
Mar 31, 2014 150,000.00
API Access

BioRestorative Therapies Current Deferred Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=BRTX&period=max&api_key=YOUR_API_KEY